Caribou Biosciences develops cell therapies for blood cancers using gene editing. CRBU reports earnings on Wed, Nov 11, 2026. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 2 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 7 | RBC Capital | Downgrade | Hold | |
| Oct 7 | Leerink Partners | Downgrade | Hold | |
| Aug 14 | B of A Securities | Maintained | Buy |
Seasonality
How CRBU has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in CRBU in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRBU is in one of them and how their past CRBU trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CRBU in an article yet. Here's the latest on the wider market.
About Caribou Biosciences
Caribou Biosciences is a biopharmaceutical company based in Berkeley, California. It develops cell therapies for cancers of the blood, using a gene editing method built on CRISPR technology. Its lead product candidates are CAR-T cell therapies made from healthy donor cells, and they are in clinical trials for patients with lymphoma or multiple myeloma that has returned or did not respond to earlier treatment.
- Headquarters
- Berkeley, CA